Company Overview - The company in focus is Fengbei Biological (603334), which specializes in the comprehensive utilization of waste resources, particularly known for its "waste oil refining" business model, converting waste oils into biodiesel and bio-based materials [3][5] - Fengbei Biological holds EU ISCC certification and has established partnerships with leading agricultural companies and international firms like Shell and BP, positioning itself as a top player in the domestic biodiesel industry [3] Financial Performance - From 2022 to 2024, the company's revenue is projected to increase from 1.709 billion to 1.949 billion yuan, while the net profit attributable to shareholders is expected to decline from 133 million to 124 million yuan, indicating a "revenue growth without profit growth" scenario [5] - The Q3 2025 report shows revenue of 2.251 billion yuan and a net profit of 117 million yuan, reflecting year-on-year growth of 62.32% and 35.32% respectively, but the net profit margin has decreased from 6.97% in the first half of 2024 to 5.21% [5] Market Reaction - After its debut on November 5, the stock experienced a significant drop, with seven out of nine trading days closing lower, plummeting from a peak of 76 yuan to around 47 yuan, highlighting a volatile market response [11][13] - The stock initially surged by 172% on the first day but faced a sharp decline of 14.4% the following day, leading to substantial losses for investors who bought in at higher prices [11][13] Investor Sentiment - Investors expressed frustration over the perceived manipulation of the stock, with claims that the actual controller had already profited through related transactions and cash dividends prior to the IPO, totaling over 65 million yuan [9] - The situation has raised concerns about the role of the underwriting institution, which is seen as prioritizing profit over the quality of the offering, leading to a sentiment of betrayal among retail investors [9][13]
惨！新股上市9天跌7天，从76跌到47，散户：这是来卖公司的吧！